NAD+ IV Therapy vs Subcutaneous Injection: When Each Makes Sense

Medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP, FNP-BC. Last reviewed May 27, 2026.

The short answer

NAD+ IV therapy and subcutaneous NAD+ injection deliver the same molecule into the same circulation. The differences are dose per session, clinical setting, peak plasma curve, and cost.

IV delivers a 500 to 1500 mg dose over 60 to 90 minutes in a clinic at $500 to $1500 per session. Subcutaneous injection delivers 100 to 200 mg per dose at home in 30 seconds at roughly $4 to $8 per dose. Twice-weekly injection covers the same weekly total NAD+ as one monthly IV session and costs about 10 percent as much.

IV is the right tool for acute loading: addiction recovery, severe chronic fatigue protocols, and longevity-stack initiation. Injection is the right tool for maintenance, on-going restoration in adults over 40, and any protocol that runs more than a month. Many patients start with IV loading at a clinic and transition to home injection for maintenance.

What NAD+ IV therapy actually is

NAD+ IV therapy is delivery of nicotinamide adenine dinucleotide directly into a peripheral vein over a 60 to 90 minute drip. Doses range from 500 mg to 1500 mg per session. The molecule enters systemic circulation immediately, with peak plasma NAD+ during the drip itself and gradual decline over the following 24 to 72 hours.

Most clinics deliver NAD+ IV in an IV-lounge setting alongside related infusions (hydration, B-vitamins, glutathione, vitamin C). A clinician supervises. The drip rate is throttled to control the flushing and chest-tightness reaction NAD+ causes at higher infusion rates. Slower drips are more comfortable; faster drips finish in 45 minutes but are harder to tolerate.

What subcutaneous NAD+ injection is

Subcutaneous NAD+ injection is delivery of the same molecule into the fat layer beneath the skin using a small insulin syringe. The dose typically runs 100 to 200 mg per injection, performed at home, two to three times a week.

Absorption from the subcutaneous depot takes 30 to 60 minutes. The plasma NAD+ rise is smaller per dose than IV but the cumulative weekly exposure is comparable when injections are stacked correctly. The flushing reaction is milder because absorption is slower than IV infusion. Most patients adapt to the sensation within the first few doses.

RxPepsDirect ships NAD+ Injectable pre-reconstituted in 1000 mg multi-dose vials. Each vial covers roughly 5 weeks of twice-weekly maintenance dosing at 200 mg per injection.

Cost comparison

Bioavailability comparison

Both routes deliver NAD+ directly to systemic circulation, bypassing the digestive degradation that limits oral bioavailability. IV produces a sharper plasma peak; injection produces a flatter, longer plasma curve. Total area under the curve (the standard pharmacokinetic measure of how much molecule reaches the cells) is roughly comparable when weekly cumulative dose is matched.

The clinical consequence: for steady-state cellular NAD+ levels, twice-weekly 200 mg subcutaneous injections produce similar tissue NAD+ status to monthly 1000 mg IV sessions. For acute peak loading (addiction recovery, acute fatigue rescue), IV delivers a sharper single-session peak that is hard to replicate with subcutaneous alone.

Patient experience: clinic vs home

The IV experience is a 60 to 90 minute clinic visit, typically in a recliner alongside other patients receiving infusions. A clinician places the IV, throttles the drip rate, and monitors for reaction. Some patients enjoy the dedicated time and the IV-lounge social context. Others find the time commitment and the cost prohibitive for ongoing therapy.

The injection experience is 30 seconds at home, usually performed in the morning or before exercise. Patients rotate injection sites (abdomen, thigh, upper arm) and follow the prescriber’s written protocol. Most patients find the routine easy to maintain once they adapt to the injection sensation in the first few doses.

Who genuinely benefits from IV

• Acute addiction recovery protocols. The traditional NAD+ recovery loading dose is 1500 mg per day for 5 to 10 consecutive days. This dose is hard to replicate with subcutaneous injection alone. IV is the established clinical tool for this protocol.
• Severe chronic fatigue or post-viral protocols. Some chronic fatigue clinics use weekly high-dose IV NAD+ to jumpstart mitochondrial function. The acute peak plasma level appears clinically useful in this population.
• Longevity-stack initiation in the first 4 to 8 weeks. Patients starting a longevity peptide stack often use IV NAD+ as a loading phase before transitioning to home injection for maintenance. The mental model is similar to loading a creatine stack: front-load the tissue saturation, then maintain with smaller doses.
• Patients who explicitly want clinical supervision. Some patients value the in-clinic experience, the monitoring, and the social context of the IV lounge. For those patients the premium is justified by preference.

Who should choose subcutaneous injection

• Most maintenance protocols. If the goal is sustained NAD+ restoration without a specific acute loading window, twice-weekly subcutaneous injection delivers the same total weekly molecule at one-tenth the cost.
• Adults over 40 with energy or cognitive complaints. The age-related cellular shortage is real and gradual. Restoration is a steady-state problem, not an acute loading problem. Subcutaneous injection is the budget-rational solution.
• Patients optimizing a longevity stack. Once a loading phase is complete (whether via IV or initial high-dose injection), maintenance is best handled at home.
• Patients without easy access to a quality IV clinic. Many regions do not have a clinic that delivers NAD+ IV at reasonable cost or quality. At-home injection removes the geography problem.
• Anyone budget-conscious. $80 a month versus $1000 to $6000. The cost difference is dramatic and the bioavailability difference is small.

The hybrid protocol some patients use

A common approach is to start with 2 to 4 IV sessions at a clinic over the first 4 to 8 weeks (loading phase), then transition to twice-weekly home subcutaneous injection for ongoing maintenance. This captures the acute peak of IV during initiation when the tissue shortage is largest and the patient is most attentive to subjective change, then settles into the cost-rational home routine once tissue NAD+ is closer to youthful baseline.

For most patients in their late 40s and beyond, the hybrid is more dramatic-feeling than pure home injection in the first 4 to 8 weeks because the acute peak produces stronger subjective effect. For younger patients or those with smaller cellular shortage, pure home injection is usually adequate from the start.

Ready to start

For at-home subcutaneous NAD+, the RxPepsDirect catalog has NAD+ Injectable at $100 per 1000 mg vial. For needle-free dosing, NAD+ Nasal Spray covers maintenance and on-demand cognitive use. For more detail on subcutaneous injection logistics see how to get NAD+ injections online. For the broader benefits picture see what NAD+ actually does.